Infliximab for psoriasis - 29/08/11
Abstract |
This review summarizes the use of inflximab in psoriasis and other immune-mediated inflammatory disorders (IMIDs). The magnitude and speed of the response to infliximab monotherapy of moderate to severe psoriasis vulgaris is substantial, being similar to those achieved with cyclosporin. In contrast with cyclosporin, clinical improvement after the initial 3 intravenous influsions of infliximab is maintained for as long as 6 months in approximately half the patients with the absence of any additional treatment. Additionally, infliximab monotherapy normalizes keratinocyte proliferation and differentiation and markedly decreases epidermal inflammation. These results provide a convincing argument for the role of TNF-⍺ in the pathogenesis of psoriasis and for the clinical development of infliximab for the treatment of psoriasis.
Il testo completo di questo articolo è disponibile in PDF.Mappa
 | Funding sources: Centocor, Inc, a COSAT grant from the Johnson and Johnson Focused Giving Program, general support of the Clinical Research Center by Merck, Inc, and a grant from the Dr David Ju Foundation. Disclosure: Dr Gottlieb is both a consultant and investigator for Amgen, Centocor, Connetics, Biogen, Genentech, Xoma, Wyeth, Cellgate, Boeringer-Ingelheim, Quatrex, Pfizer, and Novartis. She is a consultant for Enanta, Celgene, Beiersdorf, and Roche Pharmaceuticals and an investigator for Aventis. Dr Gottlieb does not own any stock in these companies nor in any companies with which she has a business relationship. |
Vol 49 - N° 2S
P. 112-117 - agosto 2003 Ritorno al numero
Articolo precedente
- Etanercept: An overview
- Ben Goffe, Jennifer Clay Cather
- Combining the new biologic agents with our current psoriasis armamentarium
- Mark Lebwohl
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?